C. Zurth

发表

Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans

M. Kähkönen, M. Koskinen, T. Korjamo, 2021, Drug Metabolism and Disposition.

Mechanism of renal excretion of various X-ray contrast materials in rabbits.

C. Zurth, 1984, Investigative radiology.

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

S. Takano, Tomio Inoue, T. Kaneta, 2016, Annals of Nuclear Medicine.

Pharmacokinetics of continuous once‐a‐week combination 17β‐Estradiol/Low‐ or high‐dose levonorgestrel transdermal delivery systems in postmenopausal women

A. Karara, L. Harrison, N. Poola, 2014, Journal of clinical pharmacology.

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

T. Tammela, B. Ploeger, O. Petrenciuc, 2019, Targeted Oncology.

Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.

J. Höchel, M. Ludwig, C. Zurth, 2014, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.

D. Apter, K. Gemzell‐Danielsson, B. Hauck, 2014, Fertility and sterility.

Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single‐center, open‐label, randomized, crossover study

M. Ludwig, Manuela Casjens, C. Zurth, 2015, Clinical pharmacology in drug development.

Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive

Isabel Reinecke, M. Merz, C. Zurth, 2014, International journal of clinical pharmacology and therapeutics.

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.

Steven C. R. Williams, O. O'Daly, Caroline Wooldridge, 2020 .

Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.

D. Seidel, H. Gieschen, C. Zurth, 2019, Journal of Clinical Oncology.

Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography.

S. Sandmann, D. Seidel, H. Gieschen, 2018 .

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Michaela Bairlein, M. Koskinen, T. Korjamo, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Determination of onapristone and its N-desmethyl metabolite in human plasma or serum by high-performance liquid chromatography.

C. Zurth, F. Kagels, 1990, Journal of chromatography.

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

H. Mukai, A. Hosono, N. Matsubara, 2017, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

M. Koskinen, F. Huang, Pirjo Nykänen, 2021, Clinical Pharmacokinetics.

Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial

O. O'Daly, S. Williams, Fiona Patrick, 2023, Targeted Oncology.

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

H. Mukai, A. Hosono, N. Matsubara, 2017, Cancer Chemotherapy and Pharmacology.

Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women

T. Faustmann, C. Klipping, I. Duijkers, 2012, Journal of clinical pharmacology.

A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women

B. Rohde, C. Klipping, I. Duijkers, 2016, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

Effect of the antiprogestin onapristone on follicular growth in women.

H. Croxatto, A. Salvatierra, S. Beier, 1994, Human reproduction.

Simultaneous Estradiol and Levonorgestrel Transdermal Delivery from a 7-day Patch: In Vitro and In Vivo Drug Deliveries of Three Formulations

A. Karara, L. Harrison, R. Lipp, 2007, Drug development and industrial pharmacy.